GW Pharma Approved to Sell Cannabis-Based Epilepsy Drug in Europe

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the
[Read More ...]

Originally posted on GW Pharma Approved to Sell Cannabis-Based Epilepsy Drug in Europe via Vic Neufeld Medical Marijuana News